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Abstract  
 
 
Background 
Asthma is a disease of the lung and a systemic disease. Functional disorders are 
associated with multiple systemic abnormalities that have been explained by 
complexity models. The aim was to test the similarity in type and aetiology between 
the extra-pulmonary symptoms of severe asthma and symptoms of fibromyalgia. 
Methods 
100 patients recruited from a specialist severe asthma clinic and 1751 people 
reporting different functional disorder diagnoses recruited via the internet completed 
the same 60-item questionnaire.  Symptom patterns were compared between groups 
using a new measure, the symptom pattern similarity index where 0 = no 
relationship, 1 = identical patterns between groups. 
Results 
Severe asthma patients report numerous extra-pulmonary symptoms.  The similarity 
index between the symptom pattern of the asthma patients with other groups was 
irritable bowel syndrome = 0.54, chronic fatigue syndrome = 0.69, fibromyalgia = 
0.75.  The index between fibromyalgia and asthma patients with the most and least 
frequent extra-pulmonary symptoms was 0.81 and 0.55 respectively.   
Conclusions 
Patients with severe asthma have numerous extra-pulmonary symptoms similar in 
type and pattern to symptoms of fibromyalgia. The similarity of the symptom pattern 
between asthma and fibromyalgia increases as the number of extra-pulmonary 
symptoms increases as predicted by network theory and previously shown to be the 
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case with other functional disorders.  These findings support the hypothesis that 
functional disorders and extra-pulmonary asthma symptoms have a common 
complexity or network aetiology. Evidence based, behavioural interventions for 
fibromyalgia may be helpful for patients with severe asthma reporting extra-
pulmonary symptoms. 
   
 
Keywords: Severe asthma; functional disorder; fibromyalgia; network; complexity; 
biopsychosocial interaction.  
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Introduction 
Asthma a disease of the lung but also a systemic disease [1 - 3], with well-
established co-morbidities [4-6].  Although functional disorders are less commonly 
cited as co-morbidities of asthma they include fibromyalgia syndrome (FMS) [7-9], 
chronic fatigue syndrome (CFS) [9, 10] and irritable bowel syndrome (IBS) [11]).  
Functional disorders are polysymptomatic and have multiple, systemic biological 
abnormalities. Although they both involve systemic disturbance, the relation between 
the symptoms of asthma and functional disorders is unknown.  Severe asthma 
patients have a high level of extra-pulmonary symptoms, some of which may relate 
to side effects of treatment [12], so severe asthma patients provide a useful 
comparison group with functional disorders. 
Despite being described as medically unexplained symptoms, several explanations 
have been proposed for functional disorders.  The first type of explanation is that 
each of the different syndromes is caused by a specific pathophysiology that is yet to 
be discovered.  This specific pathophysiology may be linked to the immune, 
neurological and endocrine abnormalities that are associated with functional 
disorders [13-20]. The second type of explanation is that all the functional disorders 
are caused by a common psychological mechanism [21], such as somatization 
(hence, somatoform disorders) or some form of cognitive disturbance [22,23]   A 
third type of explanation, commonly labelled biopsychosocial,  combines 
psychological and biological mechanisms in a single model in order to explain both 
the biological and psychological abnormalities of functional disorders.  These models 
take a variety of forms, for example, combining neural and psychology[24], neural, 
gut and psychology [25] and neural, immune, endocrine and psychology [26].   
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A common theme in the biopsychosocial models is that the body is an adaptive 
system, and symptoms are the result of some form of adaptation to situational or 
behavioural events [24,26].  Because complex network structures provide the 
architecture for learning (i.e., adaptation) in artificial intelligence systems, it has been 
suggested that complexity theory may provide insights into the underlying 
mechanisms [27].    The adaptive network theory applies network theory to a 
biological system with biopsychosocial inputs.  The theory assumes that biological 
pathology causing mechanisms are causally connected in a network, which then 
adapts according to network learning rules [28,29].  Adaptation results from inputs to 
the network which include psychological as well as biological inputs, and the 
resulting biological adaptation is associated with somatic and psychological 
symptoms. 
The symptoms of functional disorders are to some extent shared between different 
functional disorders [30]. Psychological models of functional disorders explain 
commonality in symptomatology across functional disorders. Biological explanations 
explain the specificity of symptoms between functional disorders.  Biopsychosocial 
theories explain both the specificity and commonality that is a feature of functional 
disorders [30].   The adaptive network theory, however, makes one additional 
prediction compared to other biopsychosocial theories, namely, that the commonality 
between functional disorders increases with severity.  This prediction stems the 
assumption of a network structure.  In a network of mutually activating nodes, 
increase in one part of the network activates increases activity across the whole 
network, such that differentiation between the original activating site and elsewhere 
becomes lost as severity increases.  This prediction has been confirmed using a 
machine learning form of analysis with the additional finding that the connection 
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strengths between the outgoing connections also increased with severity, showing 
that the underlying network structure (and therefore adaptation) varies with severity 
[29]. 
If the polysymptomatic presentation of IBS, FMS and CFS is due to a causal network 
of biological, symptom causing mechanisms, then it is plausible that asthma causing 
mechanisms as well as systemic effects of treatment could be causally linked to this 
network to a greater or lesser extent.  If the extra-pulmonary symptoms of asthma 
have the same network aetiology as IBS, FMS and CFS then the symptomatology 
should exhibit the same properties.   
Two predictions stem from the hypothesis that the functional disorder symptoms and 
the extra-pulmonary symptoms of asthma have the same etiology.  First, the relative 
frequency of the different extra-pulmonary symptoms in a group of patients with 
severe asthma should be similar to the relative frequency of those symptoms in 
groups of  people diagnosed with IBS, FMS and CFS.  Second, the degree of 
similarity should be greater in those asthma patients with more extra-pulmonary 
symptoms.  Previous research shows that as symptom frequency increases, the 
pattern of symptoms (i.e., relative frequency of symptoms) in functional disorder 
groups become more similar to those with fibromyalgia [29].  Therefore, the extra-
pulmonary symptoms of people with severe asthma should approximate more to the 
symptom pattern of fibromyalgia as the number of extra-pulmonary symptoms 
increases. 
The symptom pattern is defined by the relative frequency of one symptom to all 
others symptoms in a group of people, so the symptom pattern is independent of the 
absolute frequency of symptoms.  For example, if symptom A is twice as common as 
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symptom B in one group of patients, and the same ratio is found in another group, 
then the two groups have the same symptom pattern even though the absolute 
frequency of symptoms may be different between the two groups.   
This paper has three aims. The first is to compare the type and number of extra-
pulmonary symptoms of severe asthma and with the polysymptomatic presentation 
of IBS, FMS and CFS.  A second aim is to use a quantitative method to assess the 
degree of similarity between the symptom pattern of severe asthma and those of 
people with IBS, FMS and CFS in order to determine which of these three functional 
disorders is most similar to severe asthma.  A third aim is to test the hypothesis that 
those severe asthma patients with the more extra-pulmonary symptoms are more 
similar in symptom pattern to FMS compared to those asthma patients with less 
extra-pulmonary symptoms – i.e., that the extra-pulmonary symptoms of asthma 
exhibit the same property of convergence with severity as do functional disorders 
and predicted by an underlying network mechanism. 
Methods 
Participants 
Asthma sample:  Patients aged ≥16 years and attending a specialist severe asthma 
clinic were invited to participate as part of a questionnaire validation study [31]. All 
patients were diagnosed with severe asthma as defined by the European 
Respiratory Society (ERS) and American Thoracic Society (ATS) guidelines [32], 
and were excluded if they had another condition that could contribute significantly to 
their respiratory symptoms e.g., lung cancer, heart failure or COPD. 
Functional Disorders sample:  People over the age of 18 years were recruited through 
IBS, CFS and FMS patient self-help websites as part of another study [29]. 
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Questionnaire 
General symptom questionnaire (GSQ). The questionnaire for assessing extra-
pulmonary symptoms in asthma was selected so as to be able to provide a 
comparison with an existing data set obtained from a separate study [29].  The 
questionnaire was based on an established general population symptom 
questionnaire [33] but with items added that are indicative of functional disorders 
such as FMS and CFS (See online appencix1 for more details).  The questionnaire 
assesses the frequency of somatic and psychological symptoms on a 6 point Likert 
scale (the value scoring for each response shown in brackets): “Never or almost 
never” (1), “Less than 3 or 4 times per year” (2), “Every month or so” (3), “Every 
week or so” (4), “More than once per week” (5) or “Every day” (6).  The GSQ score 
was calculated from the mean of all items.  The number of weekly non-respiratory 
symptoms reported was calculated by counting the number of items with a score of 4 
or more. The number of daily non-respiratory symptoms was calculated by counting 
the number of items with a score of 6.  Higher scores indicate more symptoms. 
There were 60 identical symptoms for which data were obtained from the asthma 
and functional disorder groups. 
Clinic Data 
The following clinic data were obtained for the asthma sample: spirometry (%FEV1)), 
treatment step as defined by Global Initiative for Asthma (GINA) [22] and Body Mass 
Index (BMI). 
Procedure 
Asthma Sample: after providing written informed consent, participants either 
completed the questionnaires at home or during their clinic visit.  
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Functional disorder sample:  These data were collected as part of another study [29]. 
In an online survey, participants who reported having received a doctor’s diagnosis of 
IBS, CFS or FMS, provided consent and completed an online symptom questionnaire 
and indicated their age, gender.   
Questionnaires from the asthma sample were deemed incomplete if 15 or more items 
were missing. The online data collection of the functional disorder sample precluded 
missing items as only complete questionnaires could be submitted. 
Ethical approval 
Data collection from the asthma sample was approved by the Plymouth Hospitals 
NHS Trust and REC/HRA, ethical approval number 16/NE/0188, IRAS ID: 207601.  
All patients provided informed written consent.  Ethical approval for data collected 
the online study [29] was provided by the University of Plymouth, Faculty of Health 
and Human Science Ethics committee.  Participants for this study provided informed 
consent online. 
Analysis 
Descriptive statistics of symptoms within groups is provided by the percentage of 
people reporting a symptom at two levels of frequency: at least once per week and 
once per day.  
 The symptom pattern of a group is defined by the means of all the symptom scores 
of that group.  A symptom pattern similarity index was developed to compare the 
similarity of the symptom patterns between groups, where one = identical pattern 
and zero = unrelated pattern.  In order to calculate this index form, first the mean 
score for each symptom was calculated for each group (asthma, IBS, FMS, CFS).   
Each of these symptom means falls along a scale of 0 – 6, and together these 
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symptoms form the symptom pattern for any group. Two groups were defined as 
having an identical pattern if the similarity index is 1, in which each of the different 
symptom means in the two groups are same after adding a constant to all symptoms 
in one of the groups (the constant can be zero, in which case not only is the pattern 
identical but so is severity).  In order to calculate the symptom pattern similarity index 
between zero and one, Pearson correlations were calculated where symptoms are 
treated as cases and groups as variables.  We refer to this calculation as a symptom 
pattern similarity index rather than a correlation coefficient to avoid confusion with 
the traditional use of correlation.  Note that if the correlation were negative this would 
create a dissimilarity index where -1 = absolute opposite of pattern.  Further details 
about this index are provided in the appendix 1 (why a Pearson rather than a 
Spearman and the dissimilarity index). 
In order to examine to what extent the symptom pattern index of one group was a 
unique contributor to the symptom pattern of another, multiple regressions were 
carried out using the means of symptoms scores for each of the groups as predictor 
and dependent variables. 
Funding source 
Data collection was supported by a non-promotional grant from AstraZeneca 
 
Results 
Participants:  Of the 174 patients with severe asthma asked to take part, 20 declined 
and of the remaining 154 participants, 53 did not return their questionnaires by post, 
and one participant missed out 20 questions from the GSQ making the data 
ineligible. Completed questionnaires were received from 100 patients.  
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 Of the 1751 functional disorder participants who completed online questionnaires in 
a separate study [18], 900 people reporting a single functional disorder diagnosis of 
whom 370 reported IBS, 384 reported FMS and 146 reported CFS and are included 
for comparison.  The remaining 851 had some combination of IBS, FMS and CFS. 
Demographic data and mean questionnaire data of the severe asthma and functional 
disorder samples (IBS, FMS, CFS) is shown in Table 1.  The frequency of weekly 
and daily extra-pulmonary symptoms (i.e., GSQ items) for all four groups is shown 
Table 2.  Table 2 is limited to the 40 most frequent weekly extra-pulmonary 
symptoms reported in the asthma sample.  The full list of symptoms is shown in the 
online appendix 2.  Figure 1 provides a graphical representation of the same data, in 
order to show how the pattern of IBS, FMS and CFS groups differs from that of the 
severe asthma group.  The symptom pattern of the severe asthma group forms a 
decreasing monotonic line because the symptoms have been ordered in terms of 
their mean values. 
The median number of daily extra-pulmonary symptoms reported by the severe 
asthma sample was 6 and of weekly extra-pulmonary symptoms was 21.  Four 
asthma patients reported zero weekly non-respiratory symptoms and 19 reported 
zero daily non-respiratory symptoms. 
The means of each symptom in the different groups is shown in appendix 2. The 
symptom pattern similarity index (i.e., the metric of how similar the pattern of 
symptomatology is between groups) is shown in Table 3.  The results show that the 
symptom pattern of severe asthma is most similar to FMS (the index = 0.75) followed 
by CFS (0.66) followed by IBS (0.57). The highest symptom pattern similarity index 
is between FMS and CFS (0.88). 
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In order to test whether the symptom pattern similarity index varies with severity, the 
severe asthma sample was dichotomised to two groups based on the patients’ mean 
GSQ scores:  Those below the median GSQ score (severe asthma-low) and those 
above the median GSQ score (severe asthma-high), there being 50 patients in either 
group.  The mean symptom scores for these two asthma groups is shown in 
appendix 2, a graphical representation is shown in Figure 2 and the correlations in 
Table 3.   
Two multi-variable linear regressions were carried out to assess whether the 
symptom patterns of FMS and IBS (i.e., the mean symptom scores of the FMS and 
IBS groups) were predictors of (a) the symptom pattern of the severe asthma-high 
group and (b)  the symptom pattern of the severe asthma-low group (i.e., the mean 
symptom scores of the dichotomised asthma groups). In these multi-variable 
regressions, only the pattern of FMS (p < .001, beta = .79) but not the pattern of IBS 
(p = 0.71, beta = 0.37) predicted the pattern of severe asthma-high. Both the pattern 
of FMS (p = 0.014, beta = 0.31) and the pattern of IBS (p = 0.001, beta = 0.42) 
predicted the pattern of severe asthma-low. 
Discussion  
The result of this survey shows that the majority of patients attending a severe 
asthma clinic report many different extra-pulmonary symptoms.  The number of 
different extra-pulmonary symptoms reported varies between patients with a median 
of 21 symptoms per week and only a small minority reporting none.  Inspection of the 
type of symptoms reported shows that they are similar to the polysymptomatic 
presentation of patients with IBS, and CFS, but particularly FMS.  For example, 35% 
of the asthma patients reported, the symptom of ‘pain moving from one part of the 
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body to another on different days’ at least once per week.  This symptom, reported 
by 89% of the FMS patients is indicative of central sensitivity syndrome [13] rather 
than damage.  Cognitive disturbance of various kinds were reported by about 50% of 
the asthma patients, and although this symptom is less common than the FMS 
patients (where it is about 90%) it is nevertheless a symptom often referred to as 
‘fibro-fog’ [34] by FMS patients but also common in CFS patients.  Stomach pain was 
reported by 20% of the asthma patients weekly, compared to 79% for IBS. The 
levels of depression (36%) and anxiety (45%) are comparable to those of an 
international survey of severe asthma [35]. 
Similarity in symptoms between two groups does not mean similarity of cause.  
Irritability is a symptom of all four groups but is also a side effect of oral 
corticosteroids. In order to examine evidence for similarity of cause, we developed a 
metric, the symptom pattern similarity index, varying between 0 and 1 to express the 
extent to which the pattern of symptoms is similar between groups, independent of 
the overall frequency of symptoms (1 = the patterns are identical; 0 = patterns are 
unrelated).  Using this metric, symptom pattern similarity index of the severe asthma 
sample is most similar to the FMS group (0.75) and least similar to the IBS group 
(0.57).  Figure 1 provides a graphical representation of the difference between 
symptom similarity and symptom pattern similarity.  Of the three groups, the mean 
symptoms of the IBS are most similar to the severe asthma group.  However, the 
symptom pattern index, however, is defined by the relationship between the means 
of symptoms within a group, not by the means themselves.  The line in Figure 1 
formed by the FMS group is almost entirely above that of the severe asthma, but 
because it approximates more to a line parallel to the severe asthma group, the 
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correlation between the FMS and severe asthma group is greater than that between 
the IBS and severe asthma group. 
Network theory suggests that similarity between groups should increase with severity 
because increased severity is associated with increased pathology over the whole 
network. Therefore symptom patterns within different diagnostic groups should 
converge as severity increases, consistent with evidence elsewhere that people 
diagnosed with IBS or CFS become more similar to the more severe group of FMS 
as the frequency of IBS and CFS symptoms increases [29].  We found that people 
reporting a diagnosis of FMS report the most frequent symptoms compared with IBS 
and CFS (see Table 1).  We found that those asthma patients who had more extra-
pulmonary symptoms were more strongly related to the FMS group using our index 
(0.81) compared to those with less extra-pulmonary symptoms (0.55).   Figure 2 
provides a graphical representation of these data.  The severe asthma high and 
severe asthma low lines are approximate mirror images of each other as the mean 
values of the high and low groups are the same  as the means for the total group – 
and therefore the decreasing line shown in Figure 1.  However, in this case, the 
mean values of the severe asthma-high group are similar to the mean values of the 
FMS group, and peaks and troughs of the severe asthma-high line tend mirror the 
peaks and troughs of the FMS line, showing that the FMS and severe asthma-high 
groups tend to be parallel, though in this case not monotonic.  By contrast, the peaks 
and troughs of the severe asthma-low line tends to oppose the peaks and troughs of 
the FMS lines.  As the correlation shows in Table 3, the pattern index of the severe 
asthma-high group is more similar to the FMS group than it is to the severe asthma-
low group.  
 
15 
 
This correlation coefficients and graphs show that not only are the extra-pulmonary 
symptoms of asthma similar (though for most symptoms less frequent) than those 
reported by FMS, but also that the extra-pulmonary symptoms exhibit the same 
property of convergence with severity as predicted by network theory.  The property 
of convergence with symptom pattern FMS can be explained by a biopsychosocial 
model only if it includes a network architecture.  Models without a network 
architecture explain symptoms by a combination of biological and psychological 
mechanisms.  In any population, different symptoms have different frequencies such 
that there is a symptom pattern that characterises for that population. If symptoms 
have a psychological cause, then, irrespective of whether one or several 
psychological mechanisms are involved, increase in the severity of one or more 
psychological mechanisms should increase all symptom reporting by the same 
proportional amount.  The consequence is that as the severity of the psychological 
cause increases, the symptom pattern for severe and less severe groups should be 
the same.  In the case of biological causes, then increased pathology of a biological 
cause should increase only the symptoms associated with that biological cause.  As 
our evidence shows that increase in symptom frequency is associated with a 
convergence towards the FMS symptom pattern, our data are inconsistent with non-
network explanations. 
The symptom pattern similarity index between CFS and FMS is high (0.87), 
consistent with clinical observation that the symptoms of these two groups are 
similar despite different diagnostic procedure.  However, this similarity of pattern 
makes differentiation between CFS and FMS unreliable.  The relationship between 
FMS and IBS is lower (0.57), but still moderately strong.  We wished to determine 
whether the pattern of IBS explained additional variation of the asthma pattern 
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compared to FMS. In the case of asthma patients with more extra-pulmonary 
symptoms, only FMS but not IBS was a significant independent predictor of the 
asthma pattern – i.e., any similarity in pattern between IBS and asthma can be 
entirely explained by the similarity between FMS and IBS.   In the case of asthma 
patients with less extra-pulmonary symptoms, both FMS and IBS were independent 
predictors of the asthma pattern.  We cannot say whether the latter effect occurs 
because  some of the asthma patients exhibit the IBS and some the FMS pattern, or 
whether there is a tendency for both patterns to manifest in the same patient, but the 
results are consistent with the network theory. For patients with less severe 
pathology in the network, there is greater opportunity for activation at particular 
nodes in the network (i.e., greater opportunity for localised pathology), and so there 
is less convergence between symptom patterns between groups when severity is 
low.  These findings are also consistent with a network but not other explanations, 
including non-network biopsychosocial explanations. 
Limitations 
All groups are convenience samples. Group membership of the functional disorder 
groups is based on clinical criteria that may differ from diagnostic criteria.   The 
severe asthma sample was recruited from one centre in the UK.  The prevalence of 
FMS within the asthma group could not be determined because of under diagnosis 
of FMS in clinical practice exacerbated by significant differences between different 
diagnostic criteria [36,37]. Statistical bias can arise when correlations are calculated 
from split groups.   There is no statistic available for testing whether differences in 
the symptom pattern index are significant or not.  The reason is explained in the 
appendix. 
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Conclusions and clinical relevance 
Our results support the hypothesis that the extra-pulmonary symptoms of asthma 
have a similar aetiology to FMS, and that this aetiology is based on a causal network 
of symptom causing mechanisms to which the mechanisms of asthma and its 
treatment are causally linked.  This conclusion is supported by existing data showing 
that asthma, FMS and CFS share several non-diagnostic biological abnormalities, 
including raised systemic inflammation [38-41], hypothalamic-pituitary-adrenal axis 
dysregulation [42-44] and low magnesium levels [45,46].  Evidence that fibromyalgia 
is a risk factor for asthma exacerbations [7] as are non-asthma related visits to the 
GP [47], is consistent with an inflammatory causal pathway between systemic 
inflammation and inflammation in the lung.   
There are three possible applications of network theory to the management of 
severe asthma.  First, if variation in systemic inflammation interacts with 
inflammation in the lung, then it is plausible that evidence based interventions for 
FMS will have a beneficial effect in asthma, but only for those patients with high 
levels of extra-pulmonary symptoms.  Studies on behavioural interventions for 
severe asthma are needed, and such interventions may also act to prime 
pharmacological treatments.  Second, as asthma treatments affect the immune 
system in different ways, it is plausible that systemic corticosteroids and biologic 
treatments have radically different effects on extra-pulmonary symptoms and 
therefore quality of life.  Quality of life scales currently used in severe asthma studies 
have not been optimised for this patient population [48], and may therefore 
underestimate the benefit of newer, targeted forms of treatment.  A recently 
developed quality of life scale for severe asthma [31], and the inclusion of measures 
of extra-pulmonary symptoms will provide a more valid representation of quality of 
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life and symptoms.  Third, patients’ reports of the benefit of biologic treatment varies.  
As these treatments will interact with the existing state of a network of biological 
mechanisms, it is possible that extra-pulmonary symptom patterns predict benefit 
pharmacological treatments where outcome varies.  Predictor studies for biologic 
treatments using symptom patterns may help provide a more personalised use of 
new treatments. 
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Table 1.  Characteristics of participants. 
 Severe Asthma IBS FMS CFS 
 Mean (SD)  n (%) Mean (SD) n (%) Mean (SD) n (%) Mean (SD) n  (%) 
Age 
   range 
 
52.3 (14.9) 
17 ~ 79 
- 50.35(15.66) 
18 ~ 89 
- 52.67 (11.49) 
21 ~ 90 
 44.24(14.01) 
17 ~ 76 
 
Gender         
   Female 
   Male 
 
- 63 (63) 
37 (37) 
 314 (84.9) 
56 (15.1) 
 362 (94.3) 
22 (5.7) 
 126 (86.3) 
20 (13.7) 
GSQ Average 
Score (1- 6) 
 
2.94 (1.06)  2.90 (0.78) 
 
 3.81(0.73) 
 
 3.55(0.70) 
 
 
         
FEV1 percent  
 
69.72(18.26)        
Treatment 
(GINA step) 
        
   Step 4 
   Step 5 
 61(61) 
39(39) 
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Table 2. Non-respiratory symptoms limited to the 40 (out of 65) most frequent symptoms occurring weekly in the severe asthma 
sample. The percentage and (number) of participants experiencing each symptom in four groups: severe asthma (n = 100), IBS 
(n= 370), FMS (n = 382) and CFS (n = 146). 
  Weekly Symptom  Daily Symptom 
Symptoms 
Severe 
Asthma 
IBS FMS CFS 
  
Severe 
Asthma 
IBS FMS CFS 
Waking up still feeling tired 73.7 75.4 96.9 95.2  45.5 36.2 78.9 78.1 
  73 279 372 139  45 134 303 114 
Waking up often at night 69.7 62.4 89.8 74.0  38.4 26.2 58.1 39.0 
  69 231 345 108  38 97 223 57 
Fatigue for no reason 61.5 62.2 95.3 95.9  27.1 19.7 64.8 78.1 
  59 230 366 140  26 73 249 114 
Easily feel too hot/sweating 61.0 51.1 79.7 75.3  28.0 20.5 45.6 36.3 
  61 189 306 110  28 76 175 53 
Feeling out of breath for no reason 58.6 26.5 52.1 62.3  27.3 6.8 20.8 20.5 
  58 98 200 91  27 25 80 30 
Difficulty getting to sleep 58.0 49.2 79.9 72.6  28.0 14.9 45.8 36.3 
  58 182 307 106  28 55 176 53 
Hands tremble or shake 57.0 18.1 48.4 46.6  25.0 4.6 11.2 10.3 
  57 67 186 68  25 17 43 15 
Irritable 55.6 55.4 71.4 63.0  15.2 13.8 21.1 14.4 
  55 205 274 92  15 51 81 21 
Difficulty concentrating 53.1 51.9 90.4 93.8  14.3 14.6 49.2 54.1 
  52 192 347 137  14 54 189 79 
Itchy skin 51.5 41.6 66.7 41.8  21.2 14.9 23.7 8.9 
  51 154 256 61  21 55 91 13 
Fatigue increasing the day after you are active 50.0 40.5 93.0 97.9  28.3 12.7 54.4 61.6 
  46 150 357 143  26 47 209 90 
Itchy eyes 49.0 36.2 57.8 45.2  13.0 8.6 20.8 8.2 
28 
 
  49 134 222 66  13 32 80 12 
Very cold hands or feet 48.5 59.7 79.4 72.6  25.3 30.3 46.9 47.3 
  48 221 305 106  25 112 180 69 
Memory problems 48.0 48.6 90.4 91.1  20.0 14.3 52.3 58.2 
  48 180 347 133  20 53 201 85 
Back pain 47.9 45.9 87.5 58.2  24.5 15.1 58.6 28.8 
  45 170 336 85  23 56 225 42 
Urinating two or more times per night 47.0 32.2 46.1 39.7  27.0 14.1 25.3 17.1 
  47 119 177 58  27 52 97 25 
Thirsty all the time 47.0 40.0 68.8 52.7  18.0 11.4 33.6 28.8 
  47 148 264 77  18 42 129 42 
Easily feel too cold 47.0 61.4 84.1 76.0  20.0 31.1 55.7 47.3 
  47 227 323 111  20 115 214 69 
Mental fog 46.9 50.5 90.9 93.2  15.3 14.3 49.0 56.2 
  46 187 349 136  15 53 188 82 
Cramps in leg, foot or bottom 46.0 26.2 59.9 39.0  15.0 1.9 19.3 4.8 
  46 97 230 57  15 7 74 7 
Feeling anxious for no reason 45.5 53.0 64.1 50.0  14.1 20.3 22.1 15.1 
  45 196 246 73  14 75 85 22 
Bloating of the stomach 45.4 81.1 66.9 53.4  5.2 30.8 17.4 12.3 
  44 300 257 78  5 114 67 18 
Sensitive or tender skin 44.9 34.6 84.6 51.4  25.5 14.6 52.6 13.7 
  44 128 325 75  25 54 202 20 
Pain in legs and arms (which is not due to hard exercise) 44.3 29.5 94.8 71.9  20.6 10.5 71.4 37.0 
  43 109 364 105  20 39 274 54 
Numbness/ tingling/ pins and needles 44.0 31.6 75.3 55.5  11.0 7.0 39.8 17.1 
  44 117 289 81  11 26 153 25 
Jittery. easily startled, often worried 44 52.7 68.8 51.4  18 19.2 25.8 17.8 
  44 195 264 75  18 71 99 26 
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Pain increasing the day after you are active 43.8 32.2 94.0 85.6  20.8 8.6 59.6 39.0 
  42 119 361 125  20 32 229 57 
Racing heart 43 34.3 53.6 56.8  17 3.8 11.2 18.5 
  43 127 206 83  17 14 43 27 
Restless legs 41.4     14.1    
  41     14    
Blocked nose 40.8 29.5 47.7 41.1  18.4 6.8 15.6 13.0 
  40 109 183 60  18 25 60 19 
Very vivid dreams 40.4 41.6 51.0 53.4  11.1 7.6 13.8 13.7 
  40 154 196 78  11 28 53 20 
Headaches 40 38.9 65.9 63.7  11 5.4 16.1 17.8 
  40 144 253 93  11 20 62 26 
More clumsy than others 39.8 32.7 69.0 69.9  17.3 9.5 26.8 28.8 
  39 121 265 102  17 35 103 42 
Swollen painful joints 39.4 22.7 66.1 39.7  18.2 8.9 38.0 10.3 
  39 84 254 58  18 33 146 15 
Swollen painful joints 39.4 0.0 0.0 0.0  18.2 0.0 0.0 0.0 
  39 0 0 0  18 0 0 0 
Chest pain 36.7 19.5 42.7 30.1  9.2 2.7 8.9 5.5 
  36 72 164 44  9 10 34 8 
Depression 36.4 34.3 53.9 38.4  17.2 13.8 26.8 11.0 
  36 127 207 56  17 51 103 16 
Running nose 36.4 33.2 41.9 32.9  9.1 9.5 11.5 9.6 
  36 123 161 48  9 35 44 14 
Face flushes 35.7 27.8 53.9 36.3  15.3 7.6 15.6 8.2 
  35 103 207 53  15 28 60 12 
Pain moving from one place of body to another on different 
days 
35.4 24.1 89.1 62.3 
 
16.7 7.3 58.6 25.3 
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Table 3. Pattern similarity indexes between groups of people 
 
   
 
Asthma IBS FMS 
Asthma 
-low 
Asthma 
-high 
Asthma 
 
   0.90 0.96 
IBS 
 
0.57   0.60 0.49 
FMS 
 
0.75 0.57  0.55 0.81 
CFS 
 
0.66 0.56 0.88 0.49 0.72 
Asthma 
-low 
    0.75 
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Figure Legends 
Figure 1.   Graphical representation of the relationship between four symptom pattern indices. The line created by the severe 
asthma group is a monotonic decreasing line because the symptoms along the x axis are ordered my magnitude of the symptom 
mean.  The symptom with the greatest mean value is to the left of the x axis.  The mean symptoms of the IBS group are most 
similar in magnitude to the severe asthma symptoms.  However, the symptom pattern index of the severe asthma group is most 
similar to the FMS group because the line created by the FMS group is most parallel to the montonic decrease of the severe 
asthma group. 
Figure 2.  Graphical relationship of the relationship between three symptom pattern indices.  The symptoms along the x axis are in 
the same order as for figure 1 so that the two asthma groups would average to the monotonic line shown in figure 1. 
